Ziosoft receives FDA Clearance for CT Cardiac function analysis


Ziosoft, Inc., a leader in advanced visualization and analysis software for medical imaging, announced that it has received 510(k) clearance from the U.S FDA approval to market two additional applications for use with the Ziostation thin-client system.

These applications enhance the productivity and diagnostic capability of physicians when evaluating patients' heart health. Both the cardiac function analysis and calcium scoring applications can be accessed throughout the enterprise on the Ziostation thin-client system to provide physicians with improved efficiency and real-time collaboration when assessing results from a CT cardiac scan.

According to the National Center for Health Statistics (NCHS) every year since 1900, except 1918, cardiovascular disease accounted for more deaths than any other single cause or group of causes of death in the United States. Nearly 2,400 Americans die of cardiovascular disease each day, an average of one death every 37 seconds. These new applications from Ziosoft will contribute to more efficient interpretation and improved communication of test results, leading to enhanced quality of care for patients.

Kazuhiko Matsumoto, Ziosoft's chief executive officer, We are proud of our long history of developing software applications which aid physicians in evaluating diseases. These latest applications will be added to Ziosoft's suite of applications for a robust cardiac tool set for the market.